N-(4-butylphenyl)-1-(4-hexoxyphenyl)methanimine | 29743-11-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(4-butylphenyl)-1-(4-hexoxyphenyl)methanimine
• 英文别名: (4-Butyl-phenyl)-[1-(4-hexyloxy-phenyl)-meth-(E)-ylidene]-amine
• CAS: 29743-11-1
• 化学式: C₂₃H₃₁NO
• 分子量: 337.505
• InChiKey: YDTFLWMDAFOTRZ-LYBHJNIJSA-N

物化性质

• 沸点：
  468.5±38.0 °C(Predicted)
• 密度：
  0.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.74
• 重原子数：
  25.0
• 可旋转键数：
  11.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  21.59
• 氢给体数：
  0.0
• 氢受体数：
  2.0

安全信息

• 海关编码：
  2925290090

文献信息

• Liquid crystal display device
  申请人：Hitachi, Ltd.

  公开号：EP0069387A2

  公开（公告）日：1983-01-12

  In a liquid crystal display device produced by forming an orientation controlling film on each surface of upper and lower substrates having an electrode, placing a liquid crystal composition between said substrates, and then sealing the periphery of the substrate, the response times, particularly those at low temperatures can be reduced by using, as the aforesaid liquid crystal composition, a liquid crystal composition which is obtained by adding a material having a glass transition temperature (Tg) of -90°C or lower to a liquid crystal material base and has a To of -82°C or lower.

  在通过在具有电极的上下基板的每个表面上形成取向控制膜、在所述基板之间放置液晶组合物、然后密封基板外围而生产的液晶显示设备中，通过使用作为上述液晶组合物的液晶组合物，可以缩短响应时间，特别是在低温下的响应时间，该液晶组合物是通过在液晶材料基体中添加玻璃化转变温度（Tg）为-90°C 或更低的材料而获得的，其 To 为-82°C 或更低。
• JPS5951968A
  申请人：——

  公开号：JPS5951968A

  公开（公告）日：1984-03-26
• METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS
  申请人：Srivastava Rakesh K.

  公开号：US20080214547A1

  公开（公告）日：2008-09-04

  This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.
• US4733949A
  申请人：——

  公开号：US4733949A

  公开（公告）日：1988-03-29
• US7915245B2
  申请人：——

  公开号：US7915245B2

  公开（公告）日：2011-03-29

表征谱图